These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12538443)

  • 1. Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
    Fleming T; Borer J; Armstrong PW; Pfeffer M;
    Circulation; 2003 Jan; 107(2):e9002-3. PubMed ID: 12538443
    [No Abstract]   [Full Text] [Related]  

  • 2. Carvedilol and the Food and Drug Administration approval process: an introduction.
    Fisher LD; Moyé LA
    Control Clin Trials; 1999 Feb; 20(1):1-15. PubMed ID: 10027497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing.
    Fisher LD
    Control Clin Trials; 1999 Feb; 20(1):16-39. PubMed ID: 10027498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study.
    Kim EJ; Song WH; Lee JU; Shin MS; Lee S; Kim BO; Hong KS; Han SW; Park CG; Seo HS
    Hypertens Res; 2014 Jan; 37(1):50-6. PubMed ID: 24026037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carvedilol following AMI.
    Herner SJ; Seaton TL
    J Fam Pract; 1997 Oct; 45(4):288-9. PubMed ID: 9379146
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients.
    Jonsson G; Abdelnoor M; Müller C; Kjeldsen SE; Os I; Westheim A
    Cardiology; 2005; 103(3):148-55. PubMed ID: 15785019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial].
    Costalunga A; Gavazzi A
    Ital Heart J Suppl; 2001 Nov; 2(11):1246-7. PubMed ID: 11775420
    [No Abstract]   [Full Text] [Related]  

  • 9. Coreg. New indication for heart failure drug.
    Nursing; 2002 Feb; 32(2):18. PubMed ID: 11924159
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
    Giugliano D; Acampora R; Marfella R; De Rosa N; Ziccardi P; Ragone R; De Angelis L; D'Onofrio F
    Ann Intern Med; 1997 Jun; 126(12):955-9. PubMed ID: 9182472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
    Dargie HJ
    Lancet; 2001 May; 357(9266):1385-90. PubMed ID: 11356434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Carvedilol in combined therapy of patients with Q myocardial infarction].
    Sadionchenko VS; Iakovleva MS; Shekhian GG; Mironova MA
    Ter Arkh; 2005; 77(8):14-9. PubMed ID: 16206599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antihypertensive drugs on central blood pressure: new evidence, more challenges.
    Pucci G; Battista F; Schillaci G
    Hypertens Res; 2014 Jan; 37(1):10-2. PubMed ID: 24048493
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
    Ruilope LM
    Am J Hypertens; 1994 Feb; 7(2):129-36. PubMed ID: 7910028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
    Go AS; Yang J; Gurwitz JH; Hsu J; Lane K; Platt R
    Am J Cardiol; 2007 Aug; 100(4):690-6. PubMed ID: 17697830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is validation of non-invasive hemodynamic measurement devices actually required?
    Salvi P
    Hypertens Res; 2014 Jan; 37(1):7-9. PubMed ID: 24048491
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy of native carvedilol in patients with essential hypertension].
    Yang T; Zhang Z; Jia Z; Lin S; Peng Y
    Hunan Yi Ke Da Xue Xue Bao; 1999; 24(2):153-6. PubMed ID: 11938776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
    Bourassa MG
    J Am Coll Cardiol; 2005 Mar; 45(5):720-1. PubMed ID: 15734616
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
    Otterstad JE; Ford I
    Eur J Heart Fail; 2002 Aug; 4(4):501-6. PubMed ID: 12167391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol.
    Marchi F; Ciriello G
    Adv Ther; 1995; 12(4):212-21. PubMed ID: 10155349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.